Company: IMCR
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001671927-25-000018
Chunk: 52

Company: Immunocore Holdings plc
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 52
---
95,886— — — 1,866 — — 1,866 Share-based compensation expense—— — — 9,786 — — 9,786 As of September 30, 202550,467,954$135 5,793,501$1 $1,227,649 $(801,215)$(30,006)$396,564 

The accompanying notes form an integral part of these condensed consolidated financial statements.

4

Immunocore Holdings plc

Condensed Consolidated Statements of Shareholders’ Equity

(Unaudited) (In thousands, except share data)

Ordinary SharesDeferred SharesAdditional Paid-in  CapitalAccumulatedDeficitAccumulated Other Comprehensive  (Loss) IncomeTotal Shareholders' EquitySharesAmountSharesAmountAs of December 31, 202349,725,649$134 5,793,501$1 $1,149,643 $(744,674)$(36,261)$368,843 Net loss— — — — — (24,436)— (24,436)Other comprehensive income— — — — — — 897 897 Exercise of share options280,436 1 — — 5,212 — — 5,213 Share-based compensation expense— — — — 9,017 — — 9,017 As of March 31, 202450,006,085$135 5,793,501$1 $1,163,872 $(769,110)$(35,364)$359,534 Net loss—— —— — (11,616)— (11,616)Other comprehensive income—— —— — — 944 944 Exercise of share options11,521— —— 297 — — 297 Share-based compensation expense—— —— 9,978 — — 9,978 As of June 30, 202450,017,606$135 5,793,501$1 $1,174,147 $(780,726)$(34,420)$359,137 Net income—— — — — 8,736 — 8,736 Other comprehensive income—— — — — — 3,247 3,247 Exercise of